Shareholding pattern data is currently unavailable for this company. Please check back later.
There is currently no consolidated profit & loss data available for this company. Please switch to Standalone to view available financials.
There is currently no consolidated balance sheet data available for this company. Please switch to Standalone to view available financials.
There is currently no consolidated cash flow data available for this company. Please switch to Standalone to view available financials.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Suresh G Kare & Aruna Kare
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ms. Aditi M Panandikar & Ms. Madhura Suresh Kare
Transcript of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30-09-2026
Audio recording of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 2026
Indoco''s Clinical Research Orgainsation - AnaCipher receives approval from ANVISA Brazil for its clinical and bioanalytical facilities
Approval of the Financial Results for the Quarter and Half Year Ended 30th September, 2026
Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 27th October, 2026 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 2026 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results
Pursuant to Regulation 30 of SEBI LODR, this is to inform you that the Nomination and Remuneration Committee in its meeting held today i.e. 27th October, 2026 has approved the allotment of 14,850 Equity shares of face value of Rs. 2 each to the Indoco Employees Welfate Trust as per Indoco Remedies Limited Employee Stock Option Plan 2022
Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve A meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 27th October,2026 inter alia, to consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30th September, 2026.
Attached the certificate issued by MUFG Intime India Private Ltd, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI(D & P) Regulations,2018 for the qtr ended 30-09-2026
Intimation of Earnings Conference Call on Unaudited Financial Results for Quarter ended 30th June, 2026
Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter Ended 30th June, 2026.
Intimation regarding Closure of Trading Window
There is currently no consolidated quarterly financial results available for this company. Please switch to Standalone to view available financials.
Financial ratio data is currently unavailable for this company. Please check back later.